Month: May 2024

Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation therapeutic in AML IND filing submitted for FHD-909, a first-in-class oral BRM (SMARCA2) selective inhibitor; Phase 1 trial planned to begin in the second half of 2024 with primary target population in BRG1 mutated non-small cell lung cancer; first BRM selective inhibitor to enter the clinic IND-enabling studies for Selective CBP degrader program on track to begin by year-end 2024 Data presented at AACR support monotherapy activity and first-in-class potential for historically challenging targets including FHD-909, Selective CBP degrader and Selective EP300 degrader programs Cash, cash equivalents, and marketable securities of $206.7 million,...

—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials— RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. “We are off to a fantastic start to the year with outstanding ORLADEYO revenue growth and our prioritized pipeline programs advancing on schedule. We are focused on continuing this momentum as we see strong patient demand for ORLADEYO and more pipeline programs advancing into the clinic, starting later this year,”...

Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million representing 64% year-over-year growth Contract executed with second large group purchasing organization (GPO) for potential coverage of Auvelity Positive pivotal Phase 3 trial results of AXS-12 in narcolepsy announced Topline results of ADVANCE-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation and FOCUS Phase 3 trial of solriamfetol in ADHD both anticipated 2H 2024 ACCORD-2 Phase 3 randomized withdrawal trial of AXS-05 in Alzheimer’s disease agitation initiated; enrollment completion anticipated mid-year 2024 PARADIGM and ENGAGE Phase 3 trials of solriamfetol in major depressive disorder...

Net profit margin increased to 6.4% in 2023, up from 6.1% in 2022 Capital from IPO driving new customer acquisitions and production capacity expansion International expansion and innovative product launches position LOBO for growth in 2024 WUXI, China, May 06, 2024 (GLOBE NEWSWIRE) — LOBO EV Technologies Ltd. (Nasdaq: LOBO) (“LOBO” or the “Company”), an innovative electric vehicle manufacturer and seller, today announced its financial results for the fiscal year ended December 31, 2023. 2023 HighlightsGenerated $15.5 million revenue in 2023, down from $18.3 million in 2022 Operating expenses decreased to $1.4 million in 2023, down from $1.5 million in 2022 Net profit margin increased to 6.4% in 2023, up from 6.1% in 2022“In 2023, we navigated through several external challenges, yet our strategic initiatives, which capitalized...